You searched for compassionate use - Page 3 of 5

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes?

March 26, 2020 / Professor Paul Knoepfler, Ph.D. / 4 Comments

Kimera-Labs-exosomes-COVID-19-novel-coronavirus-disease

When the number of stem cell clinical studies and trials listed for COVID-19 first started spiraling upward it seemed likely that stem cell clinics and other firms in that arena would get interested. I thought that we’d see the unproven regenerative medicine coronavirus bandwagon quickly grow. Unfortunately, there are reasons to be increasingly concerned here. For instance, […]

As clinics buzz about coronavirus, COVID19 patient given non-FDA-approved exosomes? Read More »

Right To Try law has a big loophole that’s an opening for bad actors

October 7, 2019 / Professor Paul Knoepfler, Ph.D. / 14 Comments

There appears to be a big, risky loophole in the relatively new national Right To Try law. Some folks apparently anticipated this problem long ago, but I think most of us weren’t aware of it. Update: More specifically, some law and policy experts were writing about this and other potential loopholes in 2018. I recommend

Right To Try law has a big loophole that’s an opening for bad actors Read More »

Probing F1 legend Michael Schumacher stem cell juice story

September 22, 2019 / Professor Paul Knoepfler, Ph.D. / 7 Comments

What’s the deal with Michael Schumacher and his Hail Mary stem cell procedure. Usually when we hear about celebrities getting unproven stem cells, it’s the celebrity themselves or their PR machine hyping it in exchange for something like free treatments or even money from those offering the stem cells for sale, but in the past

Probing F1 legend Michael Schumacher stem cell juice story Read More »

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope

September 12, 2019 / Professor Paul Knoepfler, Ph.D. / 6 Comments

A new right-to-try company called Beacon of Hope is stirring some intense discussion. State and federal right-to-try laws could potentially change the fabric of how many investigational studies are conducted. That may happen through firms like Beacon of Hope. However, we don’t know much about the firm. I’m hoping to help change that. Today’s post

Richard Garr Q&A on his new Right-To-Try firm Beacon of Hope Read More »

Stem cell clinic experimenting on patients with unapproved genetically modified ‘cancer vaccine’?

May 9, 2018 / Professor Paul Knoepfler, Ph.D. / 8 Comments

What if it seemed based on the public statements of its leader that a business was using an unapproved and unproven, genetically-modified, stem cell-based ‘cancer vaccine’ on patients? Is that possible? Sometimes I think I’ve seen and heard it all when it comes to companies marketing non-FDA approved, scientifically unproven stem cell ‘therapies’ to patients

Stem cell clinic experimenting on patients with unapproved genetically modified ‘cancer vaccine’? Read More »

Popping the bubble of stem cell populism

February 25, 2018 / Professor Paul Knoepfler, Ph.D. / 11 Comments

What happens if we mix stem cells with populism? From a populist view of stem cells, everyday patients should be able to do nearly anything they want with stem cells without any governmental interference or excessive expense. Even stem cells not proven to be safe or effective. This can sound like an appealing idea to

Popping the bubble of stem cell populism Read More »

Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics?

August 29, 2017 / Professor Paul Knoepfler, Ph.D. / 1 Comment

On one level a reasonable argument can be made for letting terminally ill patients have a right to try experimental as yet unproven therapies, but in the real world Right-To-Try laws have many downsides. On the whole, they are likely to be negative for patients as a group. Raising the stakes is a push for

Will Right-To-Try Morph into Right-To-Profit for Stem Cell Clinics? Read More »

Senate Passes Federal Right-To-Try: Poll on Your Opinion

August 4, 2017 / Professor Paul Knoepfler, Ph.D. / 4 Comments

The U.S. Senate just passed a bill that if it becomes law would codify Right-To-Try as a federal law, meaning terminally patients across the U.S. could ask their physicians and drug manufacturers to be given still investigational therapies such as still unproven stem cell therapies in development. The bill’s official name is “The Trickett Wendler

Senate Passes Federal Right-To-Try: Poll on Your Opinion Read More »

Push for National Right-To-Try Law Raises Concerns in Stem Cell Community

July 13, 2017 / Professor Paul Knoepfler, Ph.D. / 7 Comments

Right-To-Try laws have been passed in many states across America, paving the way in theory for gravely ill patients to have the right to try unproven treatments of various kinds, and now there is a serious push underway for a national Right-To-Try law. What is a Right-To-Try law? Typically, these Right-To-Try laws allow for a patient

Push for National Right-To-Try Law Raises Concerns in Stem Cell Community Read More »

Burt Northwestern Stem Cell MS Trial Part 1: Big Promise & Tough Questions

April 25, 2017 / Professor Paul Knoepfler, Ph.D. / 45 Comments

Dr. Richard Burt of Northwestern University has been doing cutting edge research on the use of stem cells for autoimmune disorders for more than a decade. The core idea behind the work that Burt and other research teams are doing is that stem cells may have revolutionary potential to somehow counteract the autoimmunity that causes

Burt Northwestern Stem Cell MS Trial Part 1: Big Promise & Tough Questions Read More »

Search Results for: compassionate use